Biomedical Occupation or Discipline – Page 9

Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies

4 months ago talkbio0Tagged biotech collaboration, Camurus, cardiometabolic health, Drug Development, eli lilly, FluidCrystal technology, incretin drugs, long-acting therapies, Obesity, pharma partnerships

Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration

BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback

4 months ago talkbio0Tagged Agonist, APJ, BioAge, Exercise, incretin therapy, Metabolic Diseases, mimetics, nanobody, Obesity, small molecule agonists

BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus

4 months ago talkbio0Tagged Acquisition, Ayvakit, Biopharma, Blueprint Medicines, elenestinib, Immunology, Infrequent, Mastocytosis, Systemic, pipeline, sanofi

Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline

Precision Medicine’s Next Frontier: Unlocking the Power of Biospecimens

4 months ago talkbio0Tagged biobanking, Biological Markers, biospecimens, Cancer Genomics, Drug Development, Multiomics, Precision Medicine, spatial transcriptomics

precision medicine; biospecimens; multi-omics; drug development; biobanking; personalized medicine; biomarkers; spatial transcriptomics; cancer genomics

InflaRx Halts Rare Skin Disease Study for Vilobelimab After Futility Signal

5 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Drug Development, Futility, INF904, InflaRx, Pyoderma Gangrenosum, vilobelimab

InflaRx; vilobelimab; pyoderma gangrenosum; futility; clinical trial; COVID-19; drug development; INF904

Vinay Prasad’s First Major Policy: Challenging Covid Vaccine ‘Dogma’ at FDA

5 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Policy, Prasad, public health medicine (field), Recommendation, Regulatory Framework, United States Food and Drug Administration, Vaccines, Vinay

Vinay Prasad; FDA; Covid-19 vaccines; policy change; clinical trials; vaccine recommendations; public health; regulatory framework

FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach

5 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Elderly (population group), Eligibility Determination, high-risk groups, Policy, public health medicine (field), United States Food and Drug Administration, Vaccines

FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health

Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707

5 months ago talkbio0Tagged Cancer Therapeutic Procedure, China, Drug Development, Licensing Deal, Neoplasms, PD-1/VEGF bispecific antibody, Pfizer, SSGJ-707, upfront payment

Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development

SpyLock Technology: Recent News on Rapid Bispecific Antibody Screening

5 months ago talkbio0Tagged BiLockCatcher, Bio-Rad, bispecific antibody screening, Drug Development, high-throughput screening, Laboratory, Pioneer Antibody Discovery, Protein Engineering, SpyLock technology, SpyTag/SpyCatcher

SpyLock technology; bispecific antibody screening; Bio-Rad Laboratories; Pioneer Antibody Discovery Platform; high-throughput screening; protein engineering; SpyTag/SpyCatcher; BiLockCatcher; drug development

Recent Developments in Building Robust Health System Partnerships for Life Sciences (2025)

5 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Biotechnology, Computer Security, Data Integration, digital transformation, health system partnerships, Primary Health Care, Salesforce Life Sciences Cloud, strategic partnerships

health system partnerships; life sciences; strategic partnerships; digital transformation; artificial intelligence; cybersecurity; primary care; biotechnology; Salesforce Life Sciences Cloud; data integration